Device Trial Radar · NCT07875270
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Oct 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- CorDx, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 15, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a prospective study for the clinical validation of the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test for the qualitative detection and differentiation of SARS-CoV-2, Influenza A, Influenza B and RSV in AN samples. Results from the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test will be compared to results from a 510(k) cleared highly sensitive, multi-analyte reverse transcriptase polymerase chain reaction (RT-PCR) test for SARS-CoV-2, Influenza A, Influenza B and RSV, such as the 510(k) cleared Cepheid Xpert Xpress CoV-2/Flu/RSV plus (K250995).
Conditions
- SARS-CoV-2 Infection
- Influenza A
- Influenza B
- RSV
Interventions
Flu A/B/COVID-19 + RSV Multiplex Rapid TestDevice
The Flu A/B/COVID-19 + RSV Multiplex Rapid Test is an investigational lateral flow immunoassay intended for the qualitative detection and differentiation of Influenza A, Influenza B, SARS-CoV-2, and respiratory syncytial virus (RSV) antigens. Participants will perform the investigational test according to the provided instructions. Test results will be evaluated for diagnostic performance against a reference molecular assay, and usability assessments will be conducted according to the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Performance of CorDx Tyfast Flu A/B & COVID-19 + RSV Multiplex Rapid Test measured by agreement with RT-PCRTime frame: The estimated length of the sample collection and testing phase is expected to be 6~35 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CorDx
Alpharetta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.